Zur Vor-Weihnachtszeit bei den Klöstern im Klösterreich Straß im Straßertale (ots) - Um die ...
Roche's Anaemia Therapies to Feature Strongly at Upcoming World Congress of Nephrology
Basel, Switzerland (ots/PRNewswire) - Nephrologists attending the upcoming World Congress of Nephrology (WCN) in Rio de Janeiro, Brazil 21-25 April will hear about a wide range of study results from Roche's robust renal anaemia clinical trial programs for its two treatments -- MIRCERA(R) and NeoRecormon(R).
Among the highlights will be two analyses on MIRCERA, Roche's new continuous erythropoietin receptor activator that is awaiting regulatory approval worldwide. The oral and poster presentations review MIRCERA's once monthly haemoglobin stability in the dialysis setting with different patient populations; and new safety data which shows the rate of haemoglobin decline after withholding once monthly MIRCERA treatment.
Eight posters feature results from trials with Roche's first anaemia drug, NeoRecormon. Highlights include further results from the GAIN trial, an observational, prospective study assessing the management of renal anaemia in more than 4,000 haemodialysis patients within everyday clinical practice in 13 European countries; three posters from the IRIDIEM study investigating anaemia management in chronic kidney disease patients with Type 2 diabetes and three posters discussing the preliminary results from the ORAMA study, which used a guideline-based computerized system for clinical decision making.
Details of the study results will be available concurrent with when they are presented at the congress. Please note all information presented at the annual meeting is embargoed for media release until the time of presentation.
@@start.t1@@ Author Abstract Title Presentation Date & Time of
Author: M. Heifets and Hemoglobin (Hb) Poster Sunday, 22 April
F. Dougherty Decline After 2007
Administration is not
C.E.R.A.'s Long Half
Author: R. Bernardo C.E.R.A. Administered Oral Monday, 23 April
Once Monthly 2007
Maintains Stable Hb
Levels in Patients
with CKD on Dialysis
Regardless of Age and
Author: A. Weinreich Effectiveness and Poster Sunday, 22 April
safety of haemoglobin 2007
epoetin beta -
results from the
period of GAIN.
Author: A. Covic Achievement of EBPG Poster Monday, 23 April
targets in Eastern 2007
and Western Europe:
Author: I. MacDougall Does a guideline Poster Monday, 23 April
based computerized 2007
attainment? - ORAMA
Author: A. Winkler Treatment of renal Poster Monday, 23 April
anaemia in clinical 2007
practice taking into
account the "European
supported by a new
computer based system
Author: P. Stevens Cardiovascular Poster Tuesday, 24
comorbidity and April 2007
in 1154 patients with
type 2 diabetes and
CKD: The IRIDIEM
Author: P. Stevens Anaemia management in Poster Tuesday, 24
1154 patients with April 2007
type 2 DM & CKD: A
snapshot of Europe
from the IRIDIEM
Author: C. Wanner Epidemiology, Poster Tuesday, 24
associated April 2007
in elderly patients
with CKD and type 2
NeoRecormon Presentations Continued
Author: P.M. Wee Immediate pain Poster Time - To be
sensation is less Announced
with s.c. NeoRecormon
compared to s.c.
Interested journalists may view the meeting schedule online at http://www.wcn2007.org.
For more information, please contact:
Sheila Gies at Roche
Abenaa Hayes at Weber Shandwick
ots Originaltext: Roche Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.ch
Sheila Gies at Roche, Tel: +973-235-4347, Mobile: +973-687-0188,
Abenaa Hayes at Weber Shandwick, Tel: +212-445-8337, Mobile: